Annexon. has filed a patent for humanized anti-C1q antibodies designed to specifically bind to C1q protein. The antibodies consist of heavy chain variable and constant regions, with the Fab region binding to C1q while the Fc region does not induce complement activity or ADCC. GlobalData’s report on Annexon gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Annexon Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Annexon, NSAID cancer drugs was a key innovation area identified from patents. Annexon's grant share as of January 2024 was 12%. Grant share is based on the ratio of number of grants to total number of patents.

Humanized anti-c1q antibody for therapeutic use

Source: United States Patent and Trademark Office (USPTO). Credit: Annexon Inc

The patent application (Publication Number: US20240025974A1) discloses a humanized antibody designed to specifically bind to a C1q protein. The antibody consists of a heavy chain variable region with an Fab region for binding to the C1q protein and a human heavy chain constant region with an Fc region that does not bind to the C1q protein, induce complement activity, or antibody-dependent cellular cytotoxicity (ADCC). The human IgG4 heavy chain constant region is utilized, with specific amino acid sequences and modifications to inhibit interactions with Fc receptors.

Furthermore, the patent application includes claims related to the amino acid sequences of the heavy chain variable domain and light chain variable domain of the antibody, as well as isolated polynucleotides encoding the antibody, isolated host cells containing the nucleic acid sequence, pharmaceutical compositions, methods of treating diseases associated with complement activation, kits for treatment and diagnosis, and a method for detecting synapses in an individual using the antibody. These claims highlight the potential therapeutic and diagnostic applications of the humanized antibody in targeting C1q protein and its implications in treating diseases related to complement activation. The specificity and modifications in the antibody's structure aim to enhance its efficacy and reduce unwanted immune responses, making it a promising candidate for various medical interventions.

To know more about GlobalData’s detailed insights on Annexon, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies